The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs

Abstract

Historically, advocates of randomized drug treatment trials in oncology contributed to the changing paradigm for testing cancer treatments in the U.S., which led to global efforts to generate evidence of promise in preclinical model systems and translate those findings into improved patient outcomes. In the age of genomic medicine, the challenge to speed the evolution of how clinical trials are conducted in patients with cancer continues.